HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Direct OTC Purchases With Pre-Tax Accounts Swing On ACA Change, Not Repeal

This article was originally published in The Pink Sheet

Executive Summary

Sens. Pat Roberts, R-KS, and Heidi Heitkamp, D-ND, and Reps. Lynn Jenkins, R-KS and Ron Kind, D-WI, once again introduce the Restoring Access to Medications Act, proposing amending rather than repealing ACA.

You may also be interested in...



OTC Drug Industry Could Stand To Gain With 'Pragmatist' In White House

With the Trump administration ahead, CHPA's highest regulatory priorities include eliminating a requirement from the Obama era that consumers get a prescription in order to pay for OTC drugs with pre-tax savings accounts and improving the Nixon-era monograph program.

Pre-Tax Savings Purchases Could Be Next Hatch Stamp On Supplements

The Health Savings Act introduced by Senator Hatch and Representative Paulsen would include OTCs and supplements in purchases with pre-tax savings accounts. The legislation caps users' annual deductions for supplements and homeopathics at $1,000.

CHPA Quantifies OTCs’ Overall Value To Promote Expanded Access

Information from the CHPA-commissioned study could help improve policymakers’ understanding of the costs of making OTCs less available as well as the benefits of more Rx-to-OTC switches.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS122734

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel